Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Sanchis-Borja M, Guisier F, Swalduz A, Curcio H, Basse V, Maritaz C, Chouaid C, Auliac JB. Sanchis-Borja M, et al. Among authors: curcio h. Onco Targets Ther. 2024 May 29;17:439-448. doi: 10.2147/OTT.S448909. eCollection 2024. Onco Targets Ther. 2024. PMID: 38836187 Free PMC article.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: curcio h. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
Doubre H, Greillier L, Justeau G, Ricordel C, Swalduz A, Curcio H, Bylicki O, Auliac JB, Guisier F, Bigay-Game L, Bernardi M, Pinsolle J, Amrane K, Decroisette C, Descourt R, Chouaid C, Geier M. Doubre H, et al. Among authors: curcio h. J Cancer Res Clin Oncol. 2023 Nov;149(16):15095-15102. doi: 10.1007/s00432-023-05321-w. Epub 2023 Aug 25. J Cancer Res Clin Oncol. 2023. PMID: 37626173
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Decroisette C, Greillier L, Curcio H, Pérol M, Ricordel C, Auliac JB, Falchero L, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Game L, Bernardi M, Doubre H, Pinsolle J, Amrane K, Chouaïd C, Descourt R. Decroisette C, et al. Among authors: curcio h. J Immunother. 2023 Oct 9. doi: 10.1097/CJI.0000000000000490. Online ahead of print. J Immunother. 2023. PMID: 37807621
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, Swalduz A, Wislez M, Le Treut J, Decroisette C, Basse V, Falchero L, De Chabot G, Moreau D, Huchot E, Lupo Mansuet A, Blons H, Chouaïd C, Greillier L. Auliac JB, et al. Among authors: curcio h. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241236451. doi: 10.1177/17588359241236451. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38455711 Free PMC article.
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S, Guisier F, Curcio H, Ricordel C, Demontrond P, Abdallahoui S, Baloglu S, Greillier L, Chouaid C, Schott R. Nannini S, et al. Among authors: curcio h. Curr Oncol. 2024 Mar 21;31(3):1656-1666. doi: 10.3390/curroncol31030126. Curr Oncol. 2024. PMID: 38534959 Free PMC article.
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB. Ferreira M, et al. Among authors: curcio h. Lung Cancer. 2024 Oct;196:107934. doi: 10.1016/j.lungcan.2024.107934. Epub 2024 Aug 24. Lung Cancer. 2024. PMID: 39277916 Clinical Trial.
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot JM, Duruisseaux M, Fournel P, Odier L, Demolombe S, Bizieux-Thaminy A, Peytier A, Schott R, Hominal S, Tissot C, Bombaron P, Metzger S, Donnat M, Ortiz-Cuaran S, Rosenfeld N, Pipinikas C, Saintigny P, Pérol M. Swalduz A, et al. Among authors: curcio h. J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530-9. doi: 10.1016/j.jtho.2024.12.011. Online ahead of print. J Thorac Oncol. 2024. PMID: 39694415 Free article.
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, Curcio H, Du Rusquec P, Cortot AB, Gounant V, Abbar B, Duchemann B, Giroux-Leprieur E, Pierret T, Quilot FM, Cadranel J, Fallet V. Mehlman C, et al. Among authors: curcio h. Oncologist. 2024 Dec 26:oyae312. doi: 10.1093/oncolo/oyae312. Online ahead of print. Oncologist. 2024. PMID: 39724403 Free article.
21 results